Lithium is not a standard treatment for anxiety disorders, but accumulating evidence suggests it can reduce anxiety symptoms in certain contexts, particularly when anxiety accompanies bipolar depression. In clinical trials and observational data, lithium has shown measurable anxiolytic effects, though almost always as part of a broader mood-stabilizing role rather than as a targeted anti-anxiety drug. The picture gets more complicated when you look at different types of anxiety, different formulations of lithium, and the gap between what people experience with over-the-counter lithium supplements and what controlled research has actually tested.
Anxiety in Bipolar Depression Is Where the Evidence Is Strongest
If you are looking for the most direct clinical evidence that lithium helps anxiety, it comes from studies of people with bipolar disorder who also have significant anxiety symptoms. A study examining lithium treatment in bipolar depression found that both depression and anxiety scores improved substantially over six weeks, with remission and response rates greater than 50 percent. Those improvements showed up at relatively low blood levels of lithium, averaging around 0.49 mEq/L, which is below the range typically targeted for mania prevention.1PubMed. The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression The anxiety improvement closely tracked the depression improvement, with a strong correlation between endpoint anxiety and depression scores.
This matters because anxiety is extremely common in bipolar disorder, and it tends to worsen outcomes. When lithium brings both mood and anxiety symptoms down together, it is not clear whether the anxiety relief is a direct anti-anxiety effect or a downstream benefit of stabilizing mood. The tight correlation between depression and anxiety improvement in that study suggests they may be intertwined. But from the patient’s perspective, the distinction is somewhat academic: the anxiety gets better.
A secondary analysis of the Lithium versus Quetiapine in Depression (LQD) trial found essentially no difference between lithium and quetiapine in their anxiety-reducing effects at 8, 26, or 52 weeks.2SpringerLink (Psychopharmacology). The anxiolytic effects of quetiapine and lithium and anxiety as a moderator of the antidepressant effect: a secondary analysis of the lithium versus quetiapine in depression (LQD) trial – Section: RESULTS Quetiapine is an atypical antipsychotic with known anxiolytic properties, so the fact that lithium matched it across a full year is worth noting. This trial enrolled people with treatment-resistant depression rather than bipolar disorder specifically, which broadens the population where lithium’s anti-anxiety effects have been documented.
Why Lithium Is Not Prescribed for Anxiety Alone
Despite those findings, you will not find lithium in any major guideline as a first-line or even second-line treatment for generalized anxiety disorder, social anxiety, panic disorder, or other primary anxiety diagnoses. The reasons are practical. Lithium has a narrow therapeutic window, meaning the gap between a helpful dose and a toxic one is small. Its clinical use requires regular blood monitoring. According to one recent analysis, lithium interacts with over 700 medications at various severity levels, and toxic effects can appear even when blood levels are technically within the therapeutic range.3Frontiers in Psychiatry. Retrospective analysis of lithium treatment: examination of blood levels – Section: Introduction
When effective treatments for primary anxiety disorders include SSRIs, SNRIs, buspirone, and cognitive behavioral therapy, all of which carry far lighter monitoring burdens, the risk-benefit math for prescribing lithium specifically for anxiety does not work in most cases. Lithium tends to enter the anxiety picture when it is already being prescribed for mood stabilization and the patient happens to have comorbid anxiety, or when other treatments have failed.
What Happens in the Brain
Animal research offers some clues about how lithium might reduce anxiety at a biological level. In mice, lithium at moderate doses reversed anxiety-related behavior and lowered levels of glutamate and nitrite in the brain, suggesting involvement of the nitric oxide signaling pathway.4PubMed. NO-sGC-cGMP signaling influence the anxiolytic like effect of lithium in mice in light and dark box and elevated plus maze Glutamate is the brain’s primary excitatory chemical, and excess glutamate activity has been linked to anxiety. Bringing it down is one plausible route to anxiolysis.
A separate study in adolescent rats exposed to chronic stress found that lithium reversed both anxiety-like and depressive behaviors in a dose-dependent fashion. The mechanism appeared to involve two molecular players in the prefrontal cortex: lithium increased levels of BDNF, a protein that supports nerve cell health and growth, and suppressed GSK-3 beta, an enzyme implicated in inflammation and neurodegeneration.5PubMed. The effect of lithium on behavioral functions in adolescent rats exposed to chronic unpredictable mild stress with respect to brain-derived neurotrophic factor and glycogen synthase kinase-3 beta levels in the prefrontal cortex Both pathways are considered relevant to human mood and anxiety disorders, though translating rodent findings to human clinical practice always involves a leap.
These animal models are consistent with the idea that lithium has genuine anti-anxiety properties beyond simply stabilizing mood cycles. But they also show that the effect depends heavily on dose and context. In the rat study, only stressed animals showed robust anti-anxiety benefits; in unstressed controls, lithium at one dose actually reduced activity, hinting that the drug does not simply calm everything down indiscriminately.
PTSD and Fear-Based Anxiety
There has been theoretical interest in whether lithium could help prevent or treat post-traumatic stress disorder, which is fundamentally an anxiety disorder rooted in fear memories. A hypothesis published in Medical Hypotheses proposed that giving lithium briefly after a traumatic event might disrupt the formation of traumatic memories, potentially reducing the likelihood or severity of PTSD.6PubMed. Treatment of trauma with lithium to forestall the development of posttraumatic stress disorder by pharmacological induction of a mild transient amnesia The idea rests on lithium’s known effects on long-term potentiation, the process by which the brain strengthens neural connections in response to experiences.
The experimental evidence, however, has not been encouraging. A study in fear-conditioned rats found that lithium had no effect on freezing behavior, a standard measure of learned fear, regardless of the treatment protocol used.7PubMed. Sex difference affects fear extinction but not lithium efficacy in rats following fear-conditioning with respect to the hippocampal level of BDNF This is one of those cases where a compelling hypothesis meets a null result in the lab. That does not rule out lithium for PTSD in humans, but it means the theoretical rationale has not yet translated into demonstrable effects even in the simplest animal models. No controlled human trials specifically testing lithium for PTSD have generated strong results, and PTSD treatment guidelines do not include lithium.
When Lithium Might Make Anxiety Worse
Lithium is not uniformly calming, and in some situations it can increase anxiety. A case report documented a patient with obsessive-compulsive disorder who was stable on sertraline but developed a worsening of obsessive-compulsive symptoms when given a high dose of lithium. The symptoms improved after the lithium dose was reduced.8PubMed Central. Acute high dose lithium-induced exacerbation of obsessive compulsive symptoms OCD is classified separately from generalized anxiety in current diagnostic frameworks, but the overlap is significant, and this case illustrates that lithium’s effects on anxiety-spectrum symptoms are not always positive.
Stopping lithium can also trigger anxiety. A questionnaire survey of people who had discontinued lithium found that about one in five reported temporary symptoms of heightened anxiety, irritability, and emotional instability after withdrawal.9PubMed. Withdrawal symptoms from lithium. Four case reports and a questionnaire study A more recent synthesis of evidence across psychotropic medications confirmed that lithium discontinuation can produce anxiety, restlessness, dizziness, and irritability, particularly in the first week, though symptoms are generally mild and resolve on their own.10Molecular Psychiatry. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes – Section: Mood stabilizers Stopping abruptly rather than tapering gradually appears to carry more risk, including rebound mood episodes. Whether this withdrawal anxiety represents a genuine physiological rebound or the re-emergence of the underlying condition remains a matter of debate in the literature.11PubMed. Lithium discontinuation: withdrawal or relapse?
Lithium Supplements and Over-the-Counter Use
Prescription lithium (typically lithium carbonate or lithium citrate) and the lithium orotate sold in supplement stores are not the same thing, even though they deliver the same element. Lithium orotate is marketed in doses of roughly 5 to 20 milligrams of elemental lithium, compared to the 150 to 1,200 milligrams of lithium carbonate used in psychiatric prescriptions. Proponents of lithium orotate argue that the orotate form crosses into the brain more readily, which would theoretically allow much smaller doses to have meaningful effects.12PubMed Central. Lithium orotate: A superior option for lithium therapy? The clinical evidence for this claim, however, is thin. No large randomized trials have compared lithium orotate to lithium carbonate for any psychiatric indication, including anxiety.
A recent survey of people who purchased lithium as a supplement found that anxiety was the most common reason they believed the supplement would help. When asked about actual improvements they experienced, cognition was the most frequently reported benefit, closely followed by anxiety and mood.13SAGE Publications / Canadian Journal of Psychiatry. A Survey Exploring People’s Experiences With Lithium Bought as a Supplement – Section: Results This is self-reported and uncontrolled, so placebo effects cannot be separated from genuine pharmacological effects. But it does show that a sizable group of people are already using lithium supplements for anxiety, largely outside the view of their doctors, and reporting subjective benefit.
Ecological studies have found that communities with higher naturally occurring lithium levels in their drinking water tend to have lower suicide rates.14PubMed. Association between naturally occurring lithium in drinking water and suicide rates: systematic review and meta-analysis of ecological studies – Section: CONCLUSIONS The lithium concentrations in question are extremely low, far below therapeutic doses. This line of research is intriguing but does not directly address anxiety. The connection to suicide prevention may involve mood stabilization broadly, but the jump from population-level correlations in water supplies to individual-level treatment of anxiety symptoms is one that the data cannot currently support.
Long-Term Safety Tradeoffs
For anyone considering lithium specifically for anxiety, the long-term safety profile is a critical part of the calculation. Lithium is associated with roughly double the risk of developing hypothyroidism compared to other mood-stabilizing medications, and a moderately elevated risk of chronic kidney disease at stage 3 or above.15JAMA Network Open. Lithium for Bipolar Disorder and Risk of Thyroid Dysfunction and Chronic Kidney Disease – Section: Results A large population-based cohort study comparing lithium to alternatives like valproate, olanzapine, and quetiapine found that all three alternatives carried lower rates of kidney disease and hypothyroidism than lithium did.16PLoS Medicine. Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study – Section: Results
In very long-term use spanning decades, kidney and thyroid problems become more common. A case series of patients who had taken lithium for 40 years or more found that all five had some degree of chronic kidney disease, and one had developed Hashimoto’s thyroiditis requiring thyroid hormone replacement.17PubMed Central. Kidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients Higher lithium blood levels and episodes of lithium toxicity are associated with more kidney damage over time. These risks are considered acceptable for someone with severe bipolar disorder, where lithium is often the most effective treatment available and the alternative is recurrent mania and depression with their own serious consequences. For someone whose primary problem is anxiety, the same risks may look quite different.
This is the core reason lithium has not become an anxiety treatment despite showing anxiolytic properties: the side effect and monitoring burden is disproportionate to the problem being treated, at least when the anxiety is not part of a mood disorder that already justifies lithium. The exceptions are cases where standard anxiety treatments have failed and the clinician judges that the benefit of trying lithium augmentation outweighs the costs of monitoring and side effects.
Children and Adolescents
Pediatric data on lithium for anxiety is scarce. A review of mood stabilizers and anticonvulsants in children and adolescents with non-mood disorders found that lithium showed some promise, but the authors emphasized that larger studies were needed before ongoing use could be supported.18Ovid. Evidence for Use of Mood Stabilizers and Anticonvulsants in the Treatment of Nonaffective Disorders in Children and Adolescents Children and adolescents face the same monitoring requirements as adults, and many parents and clinicians are understandably reluctant to commit a young person to regular blood draws and a drug with a narrow therapeutic window when other anxiety treatments exist. The animal research on lithium in stressed adolescent rats is suggestive, but no controlled human trial has specifically tested lithium for pediatric anxiety disorders.
Who Might Actually Benefit
Pulling the evidence together, the people most likely to see anxiety improvement from lithium fall into a few overlapping groups. If you have bipolar disorder with prominent anxiety symptoms, lithium may help both your mood cycles and your anxiety simultaneously, and the monitoring burden is already justified by the bipolar diagnosis. If you have treatment-resistant depression with significant anxiety and your clinician is considering augmentation strategies, the LQD trial data suggest lithium performs comparably to quetiapine in reducing anxiety over the long term. And if you are already on lithium for another reason and notice that your anxiety has improved, that is consistent with what the clinical data show.
If your primary problem is an anxiety disorder without an underlying mood disorder, lithium is not where most clinicians will start, and for good reason. The monitoring, the drug interactions, the thyroid and kidney considerations, and the availability of safer first-line options all argue against it. The supplement route with lithium orotate sidesteps the monitoring issue by using far lower doses, but it also sidesteps the evidence: we simply do not have controlled trial data showing that supplement-level doses of lithium meaningfully reduce clinical anxiety. People who report benefit may be experiencing a real effect, a placebo response, or improvement from other changes they made at the same time. Until randomized trials address this directly, the honest answer is that we do not know whether over-the-counter lithium helps anxiety in any pharmacologically meaningful way.